Intelligent Bio Solutions Inc. INBS 深 沪
已收盘 08-28 16:00:00 美东时间
2.36
+0.090
+3.96%
华盛通- 最 高2.3996
- 今 开2.33
- 成交量 1.70万股
- 最 低 2.265
- 昨 收 2.27
- 总市值 714.48万
- 52周最高 24.90
- 市盈率 静 --
- 换手率 0.56%
- 52周最低 1.52
- 委 比 61.89%
- 总股本 302.75万
- 历史最高 34176.00
- 量 比 0.22
- 振 幅 5.93%
- 历史最低 1.52
- 每 手 1
- 风险率 4.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Intelligent Bio Solutions Shares Surge Monday: What's Driving the Action?
Shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) are surging Monday afternoon after the medical technology company announced a significant regulatory milestone for its rapid testing unit. Intelligent Bio Solutions stock is showing exceptional strength. Why is INBS stock up today? Strategic Ali...
08-18 03:43
Intelligent Bio Solutions Completes Usability Study For Intelligent Fingerprinting Drug Screening System To Detect Opiate Codeine
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the completion of its Usability Study for the Intelligent Fingerprinting Drug Screening System, supporting its FDA 510(...
08-05 20:37
Intelligent Bio Solutions Completes Precision Testing For Its Intelligent Fingerprinting Drug Screening System To Detect Opiate Codeine
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the completion of precision testing, a key component of the Company's FDA 510(k) submission for U.S. market clearance o...
07-21 20:32
Intelligent Bio Solutions Initiates Multi-Site Method Comparison Study To Support FDA 510(k) Submission For US Market Clearance Of Intelligent Fingerprinting Drug Screening System For Opiate Codeine
Study designed to validate accuracy and real-world workplace performance of the Intelligent Fingerprinting Drug Screening System Company expects to complete enrollment and data collection by the end of July,
06-02 20:36
Intelligent Bio Solutions Q3 EPS $(1.80) Up From $(4.40) YoY, Sales $1.060M Up From $728.867K YoY
Intelligent Bio Solutions (NASDAQ:INBS) reported quarterly losses of $(1.80) per share. This is a 59.09 percent increase over losses of $(4.40) per share from the same period last year. The company reported $1.060
05-13 20:34
Intelligent Bio Solutions Completes Penetration Testing As Part Of Its Upcoming FDA Submission
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of
04-17 20:33
Intelligent Bio Solutions Completes Its Initial Clinical Cut-Off Trial For FDA 510(k) Submission For U.S. Market Clearance Of Its Intelligent Fingerprinting Drug Screening System
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of its
04-02 20:36
Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant
Intelligent Bio Solutions Inc. (INBS) announced the grant of its eighth European patent, EP3752831, which protects advancements in contextualizing fingerprint chemical analysis with fingerprint deposition volume. This innovation enhances the interpretation of substances detected in fingerprint sweat and strengthens the robustness of the testing process, further reinforcing INBS' market position and intellectual property portfolio in Europe. The p...
03-26 12:30
